



IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

SAD
2
2-20-02

☒ In re the application of: LAUKS, Imants R.

Serial No.: 09/875,949

Group Art Unit: 1743

Filing Date: 06/08/2001

Examiner: Wallenhorst

Confirmation No.: 1788

Title: POINT-OF-CARE IN-VITRO BLOOD ANALYSIS SYSTEM

RECEIVED
AUG 28 2001
TC 1700

INFORMATION DISCLOSURE STATEMENT

Honorable Commissioner of
Patents and Trademarks
Washington, D.C. 20231
U.S.A.

Sir:

Pursuant to 37 C.F.R. 1.56, the attention of the Patent and Trademark Office is hereby directed to the reference(s) listed on the attached PTO-1449. One copy of each reference is attached. It is respectfully requested that the information be expressly considered during the prosecution of this application, and that the reference(s) be made of record therein and appear among the "References Cited" on any patent to issue therefrom.

- ☒ 1. This Information Disclosure Statement is being filed within three months of the U.S. filing date OR before the mailing date of a first Office Action on the merits. No certification or fee is required.
- 2. This Information Disclosure Statement is being filed more than three months after the U.S. filing date AND after the mailing date of the first Office Action on the merits, but before the mailing date of a Final Rejection or Notice of Allowance.
- a. Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(1).
- b. No item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(2).

— c. Attached is our cheque no. ____ in the amount of \$200.00 in payment of the fee under 37 C.F.R. 1.17(p). Please credit or debit Deposit Account No. ____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.


— d. Pursuant to the March 2, 1992 PTO Notice, no certification or fee is required for Information Disclosure Statements filed during this stage of prosecution and on or before April 30, 1992.

— 3. This Information Disclosure Statement is being filed more than three months after the U.S. filing date and after the mailing date of a Final Rejection or Notice of Allowance, but before payment of the Issue Fee. It is hereby requested that the Information Disclosure Statement be considered. Attached is our cheque no. ____ in the amount of \$130.00 in payment of the fee under 37 C.F.R. 1.17(i)(1). Please credit or debit Deposit Account No. ____ as needed to ensure consideration of the disclosed information. Two duplicate copies of this paper are attached.

— a. Each item of information contained in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application not more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(1).

— b. No item of information in this Information Disclosure Statement was cited in a communication from a foreign patent office in a counterpart foreign application or, to my knowledge after making reasonable inquiry, was known to any individual designated in 37 CFR §1.56(c) more than three months prior to the filing of this Information Disclosure Statement. 37 C.F.R. 1.97(e)(2).

Respectfully submitted,

 Dated: 23 AUG 2001

Martin J. Marcus

Registration Number: 18,823

Attorney Docket No.: PAT 506-2

Attorney Address:

Borden Ladner Gervais
1000-60 Queen Street
Ottawa, Ontario
K1P 5Y7
CANADA

Telephone No.: (613) 237-5160
Facsimile No.: (613) 787-3558



FORM PTO 1449 U.S. DEPARTMENT OF COMMERCE PATENT AND TRADEMARK OFFICE LIST OF REFERENCES CITED BY APPLICANT (Use several sheets if necessary)	ATTY. DOCKET NO.	SERIAL NO.
	PAT 506-2	09/875,949
	APPLICANT LAUKS, Imants R.	
	FILING DATE	GROUP
	06/08/2001	1743

RECEIVED
 AUG 28 2001
 TC 1700

U. S. PATENT DOCUMENTS

*EXAMINER INITIAL		DOCUMENT NUMBER	DATE	NAME	CLASS	SUBCLASS	FILING DATE IF APPROPRIATE
	AA	4,342,964	08/03/92	DIAMOND et al			02/14/80
	AB	4,734,184	03/29/88	BURLEIGH et al			02/26/87
	AC	5,096,669	03/17/92	LAUKS et al			09/15/88
	AD	5,124,661	06/23/92	ZELIN et al			07/23/90
	AE	5,282,950	02/01/94	DIETZE et al			07/14/92
	AF	5,781,024	07/14/98	BLOMBERG et al			07/26/96
	AG	5,829,950	11/03/98	ALDER			02/22/95
	AH	6,066,243	05/23/00	ANDERSON et al			07/21/98

FOREIGN PATENT DOCUMENTS

		DOCUMENT NUMBER	DATE	COUNTRY	CLASS	SUBCLASS	TRANSLATION	
							YES	NO
	AI	WO 98/37804	09/03/98	PCT				X
	AJ	WO 00/21434	04/20/00	PCT				X

OTHER REFERENCES (Including Author, Title, Date, Pertinent Pages, Etc.)

	AK		International Fed. Clinical Chem., Proceedings of the 17 th International Symposium, Nice, France June 1998, eds. P. D'orazio, N. Fogh-Andersen and L. Larsson, Omnipress, Madison, WI USA, 1998. pp 3-15

EXAMINER	DATE CONSIDERED
*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609; Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.	